Product Introduction :
Favipiravir is a drug with a new mechanism, a broad-spectrum anti-influenza drug belonging to the RNA-dependent RNA polymerase (RdRP) inhibitor class, which was launched in Japan in 2014 , Used to treat new and recurrent influenza, and become Japan's national strategic reserve drug.
Favilavir is a pyrazinamide derivative, which has the effect of reducing the activity of influenza virus, West Nile virus, yellow fever, foot-and-mouth disease virus and many other viruses. It has also been shown to inhibit activities such as enterovirus and Rift Valley fever. .
In China, favilavir has been approved for clinical trials for the treatment of COVID - 19 infection. The results of the study show that favilavir has initially shown more obvious efficacy and lower adverse reactions in the treatment of new coronary pneumonia.
For the treatment of new or re-epidemic influenza in adults (only used when other antiviral drugs are ineffective or ineffective)
Administration and Dosage :
Oral administration on an empty stomach
After the flu symptoms are discovered, the drug is administered quickly, and the course of treatment for adults usually lasts for 5 days.
On day 1, 1600 mg each time, 2 times a day; from day 2 to day 5, 600 mg each time, 2 times a day.